Patents Assigned to University of Florida
-
Patent number: 11941515Abstract: Disclosed are various embodiments of memristive devices comprising a number of nodes. Memristive fibers are used to form conductive and memristive paths in the devices. Each memristive fiber may couple one or more nodes to one or more other nodes. In one case, a memristive device includes a first node, a second node, and a memristive fiber. The memristive fiber includes a conductive core and a memristive shell surrounding at least a portion of the conductive core along at least a portion of the memristive fiber. The memristive fiber couples the first node to the second node through a portion of the memristive shell and at least a portion of the conductive core.Type: GrantFiled: June 8, 2021Date of Patent: March 26, 2024Assignee: University of Florida Research Foundation, Inc.Inventors: Juan Claudio Nino, Jack Kendall
-
Publication number: 20240090511Abstract: Provided herein are modified insecticidal proteins comprising an insecticidal protein, wherein the insecticidal protein has been modified to include at least one stink bug gut binding peptide.Type: ApplicationFiled: November 15, 2021Publication date: March 21, 2024Applicants: BASF Corporation, University of Florida Research Foundation IncorporatedInventors: Razvan Dumitru, Bryony C. Bonning
-
Patent number: 11931346Abstract: Macular degeneration, closed head injury, stroke, irritable bowel disease, and reperfusion injury are all associated with biological injury due to reactive oxygen species, probably due to focal iron overload in many instances. The present invention provides methods and pharmaceutical compositions for treating these diseases and conditions using desferrithiocin analogs of Formula (I). In certain embodiments, the analogs include a poly ether moiety at the 4?-position of the phenyl ring of the compound.Type: GrantFiled: May 14, 2021Date of Patent: March 19, 2024Assignee: University of Florida Research Foundation, IncorporatedInventor: Raymond J. Bergeron, Jr.
-
Patent number: 11932878Abstract: Provided herein are genetically engineered cells containing one or more modulated metabolic genes, where the expression of the modulated metabolic gene(s) can be greater than that of an unmodified control. Also provided herein are methods of making the genetically engineered cells using synergistic activation mediator CRISPR-Cas9. Further provided herein are high throughput assays that can employ the genetically engineered cells provided herein.Type: GrantFiled: July 7, 2017Date of Patent: March 19, 2024Assignees: University of Florida Research Foundation, Inc., The Research Foundation for the State University of New YorkInventors: Christopher Dillon Vulpe, Amin Sobh, David Michael Faulkner, Abderrahmane Tagmount, Michael Fasullo
-
Publication number: 20240083936Abstract: The disclosure relates to compounds of Formula (I), as well as compositions, methods, uses, and kits comprising the same. The compounds, compositions, methods, uses, and kits provided herein are useful in treating diseases or disorders including cancer, HIV, and angiogenesis-related disorders.Type: ApplicationFiled: December 17, 2021Publication date: March 14, 2024Applicant: University of Florida Research Foundation, IncorporatedInventors: Jane V. Aldrich, Jeremy Coleman
-
Publication number: 20240087750Abstract: h A method for using a trained machine learning model to predict risk of incident opioid use disorder (OUD) and/or of N an opioid overdose episode for a subject. The method comprises using at least one computer hardware processor to perform: accessing data associated with the subject, wherein the data comprises values for a plurality of predictors; generating input features for the trained machine learning model from the data; and providing the input features as input to the trained machine learning model to obtain an output indicative of the risk of OUD and/or of the opioid overdose episode for the subject, wherein the trained machine learning model comprises a first plurality of values for a respective first plurality of parameters, the first plurality of values used by the at least one computer hardware processor to obtain the output from the input features.Type: ApplicationFiled: June 17, 2021Publication date: March 14, 2024Applicants: University of Florida Research Foundation, Incorporated, University of Pittsburgh- Of the Commonwealth System of Higher Education, The United States Government as represented by The Department of Veterans AffairsInventors: Wei Hsuan Lo Ciganic, Walid Fouad Gellad
-
Patent number: 11926700Abstract: Biorenewable polyesters and polyester copolymers derived from camphoric acid, aromatic dicarboxylic acid and aliphatic diols and methods of making those copolyesters and articles comprising copolyesters are disclosed. The disclosed biorenewable copolyesters may can have a Mn of from about 5,000 Da to about 500,000 Da. Also disclosed are preparation methods of various monomers e.g., cis-1,4-anhydroerythritol and bis(2-hydroxyethyl) camphorate. The disclosed biorenewable polyesters and polyester copolymers can be used for production of various articles utilizing a conventional polyesters or polyester copolymers, to replace, in part or in whole, a conventional non-biorenewable polyesters or polyester copolymers.Type: GrantFiled: December 27, 2022Date of Patent: March 12, 2024Assignee: University of Florida Research Foundation, Inc.Inventors: Stephen A. Miller, Olivier Nsengiyumva
-
Patent number: 11926604Abstract: The invention is directed towards compounds, methods of stimulating myelination, stimulating proliferation of oligodendrocytes (OLs) or stimulating oligodendrocyte precursor cells and methods of treating diseases, disorders or symptoms thereof.Type: GrantFiled: May 10, 2019Date of Patent: March 12, 2024Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventor: Scott A. Rivkees
-
Patent number: 11918421Abstract: Described herein are loupes shields. The shields can be easily attached to the loupes. The loupes shield is composed of a single filter that blocks harmful light. Additionally, the loupes shield includes a connector that permits the loupes shield to be attached to the loupes lens or housing that holds the loupes lens. The loupes shields described are useful in applications where it is desirable to protect the user from being exposed to damaging light. The loupes shields are useful in dental applications such as, for example, dental restorations, where light cure is required to cure the resin applied to a tooth during a dental restoration.Type: GrantFiled: October 29, 2020Date of Patent: March 5, 2024Assignee: University of Florida Research Foundation, Inc.Inventors: Hind Sattar Hussein, Nader Farhan Abdulhameed
-
Publication number: 20240067639Abstract: Disclosed herein are compounds that selectively bind an expanded transcribed repeat r(G4C2)exp, prevent sequestration of RNA-binding proteins, and inhibit translation of repeat associated non-ATG (RAN) translation responsible for generation of toxic dipeptide repeats underlying diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The compounds and their pharmaceutical compositions are useful in treating a disease or condition characterized by an expanded G4C2 repeat RNA (r(G4C2)exp), such as ALS and FTD.Type: ApplicationFiled: September 8, 2021Publication date: February 29, 2024Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATIONInventors: Matthew Disney, Timothy Allen Blizzard, Ippei Usui
-
Publication number: 20240069039Abstract: Aspects of the disclosure relate to methods and compositions (e.g., kits) for detecting certain repeat-associated non-ATG (RAN) proteins in a subject (e.g., a subject having or suspected of having a disease associated with a CAG and/or CTG repeat expansion). In some embodiments, methods described by the disclosure comprise detecting one or more RAN proteins in a biological sample obtained from a subject by an immunoassay using one or more antibodies that target homopolymeric repeat regions of RAN proteins. In some embodiments, the disclosure relates to kits comprising one or more antibodies that target homopolymeric repeat regions of RAN proteins, and an immunoassay plate and/or reagents. In some embodiments, the disclosure provides methods of producing anti-RAN protein antibodies.Type: ApplicationFiled: October 9, 2020Publication date: February 29, 2024Applicant: University of Florida Research Foundation, IncorporatedInventors: Laura Ranum, Monica Banez Coronel
-
Patent number: 11912704Abstract: In one aspect, the disclosure relates to methods for preparation of intermediates useful for the preparation of aryl-cycloheptene scaffolds. In a further aspect, the disclosed methods pertain to the preparation of compounds comprising an aryl-cycloheptene structure. The disclosed methods utilize abundant starting materials and simple reaction sequences that can be used to modularly and scalably assemble common such cores. In various aspects, the present disclosure pertains to compounds prepared using the disclosed methods. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: GrantFiled: August 7, 2019Date of Patent: February 27, 2024Assignee: University of Florida Research Foundation, Inc.Inventors: Alexander James Grenning, Ehsan Fereyduni
-
Patent number: 11912999Abstract: An aptamer-N-heterocyclic-carbene metal complex conjugate (aptamer-NHCM conjugate) or an aptamer-bis-N-heterocyclic-carbene metal complex conjugate (aptamer-bis-NHCM conjugate) includes an aptamer coupled through a hydrolytically stable bond to an N-heterocyclic-carbene metal complex (NHCM) or a bis-N-heterocyclic-carbene metal complex (bis-NHCM). The aptamer-NHCM conjugate is prepared where the chosen aptamer displays selective binding to a cell specific receptor, such that the cytotoxic NHCM can be directed specifically to cells responsible for a target disease (e.g., a specific cancer type). A method of preparing the aptamer-N-heterocyclic-carbene metal complex conjugate involves installing a coupling group to an N-heterocyclic-carbene metal complex that can specifically bond with a functional group on an aptamer; the bond, covalent or non-covalent, is stable hydrolytically in the absence of an environment that promotes intentional cleavage of the bond.Type: GrantFiled: July 10, 2020Date of Patent: February 27, 2024Assignee: University of Florida Research Foundation, Inc.Inventors: Adam S. Veige, Mary E. Garner, Weijia Niu
-
Patent number: 11911278Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to TMJ implantation materials and implants (e.g., temporomandibular joint (TMJ) disc), methods of making TMJ implantation materials and implants, methods of forming a TMJ implantation material or an implant, and the like.Type: GrantFiled: September 25, 2020Date of Patent: February 27, 2024Assignee: University of Florida Research Foundation, Inc.Inventor: Peter S. McFetridge
-
Publication number: 20240058477Abstract: Provided for herein are polynucleotides, including codon-optimized polynucleotides, encoding genes for use in, for example, virally-mediated gene therapy for Friedreich's ataxia. Some embodiments related to viral vector constructs for use in such gene therapy. Also provided are dosing regimens and therapeutic combinations or systems for use in modulating immune responses to such viral vectors.Type: ApplicationFiled: January 4, 2022Publication date: February 22, 2024Applicants: University of Florida Research Foundation, Incorporated, AavantiBio, Inc.Inventors: Manuela Corti, Barry John Byrne, Irene Zolotukhin
-
Publication number: 20240060091Abstract: Autoregulatory systems that have been implemented to control the expression and activity of Cast 3d, including the activity of Cast 3d in vivo, thereby reducing collateral damage in cells at off-target sites (e.g., non-target messenger RNA transcripts. The autoregulatory system is in the form of a nucleic acid molecule comprising a zinc finger binding site, a promoter, and a nucleotide sequence encoding a Cast 3d fusion protein, and a transcriptional repressor domain, and wherein the Cast 3d fusion protein binds to the zinc finger binding site and represses transcription of the nucleotide sequence encoding the Cast 3d fusion protein.Type: ApplicationFiled: December 17, 2021Publication date: February 22, 2024Applicant: University of Florida Research Foundation, incorporationInventors: Eric Tzy-Shi Wang, Chase P. Kelley
-
Patent number: 11903910Abstract: The present disclosure provides the use of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) in treating a neurological disease associated with repeat expansions and/or RAN protein accumulation, reducing the level of one or more repeat associated non-ATG (RAN) proteins, and reducing the accumulation of RAN proteins in a subject and/or biological sample. Also provided is the use of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) in inhibiting RAN protein translation in a subject and in a biological sample (e.g., cells, tissue). Also provided in the present disclosure are pharmaceutical compositions, Skits, and uses of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) for treating diseases associated with repeat expansions.Type: GrantFiled: September 26, 2018Date of Patent: February 20, 2024Assignee: University of Florida Research Foundation, IncorporatedInventors: Laura Ranum, Tao Zu
-
Patent number: 11904016Abstract: The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.Type: GrantFiled: April 13, 2020Date of Patent: February 20, 2024Assignee: University of Florida Research Foundation, IncorporatedInventors: Duane Mitchell, Catherine Flores
-
Patent number: 11905524Abstract: Provided herein are compositions and methods for packaging a recombinant adeno-associated vims (rAAV) particle comprising using inverted terminal repeats (ITRs) and rep genes of different serotypes and/or using chimeric rep genes.Type: GrantFiled: March 6, 2019Date of Patent: February 20, 2024Assignee: University of Florida Research Foundation, IncorporatedInventors: Mavis Agbandje-McKenna, Mario Mietzsch, Robert McKenna
-
Publication number: 20240054745Abstract: According to at least one aspect, a series of images of a scene are obtained, such as by a head mounted display. The scene includes a medical device and a tracking device, and the series of images including at least the tracking device. Relative pose information indicative of a relative spatial relationship between the tracking device and the medical device is accessed, the 3D representation of the patient is registered with the medical device using the series of images of the scene and the relative pose information, and a mixed reality visualization of the 3D representation of the patient and the medical device generating, based on results of the registering. The mixed reality visualization can further include a visual indication indicative of an alignment of the patient with the 3D representation.Type: ApplicationFiled: December 16, 2021Publication date: February 15, 2024Applicant: University of Florida Research Foundation, IncorporatedInventor: Perry B. Johnson